insights_auto
Why is ROIV down 2.20%?
Dive Deeperchevron_right
ROIV:NASDAQ
Roivant Sciences Ltd
$34.75
arrow_downward
-2.20%(-0.78) 1D
$34.75
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 7, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$35.22
High
$35.48
Low
$34.63
Mkt. cap
25.10B
Avg. vol.
9.02M
Volume
5.74M
52-wk high
$42.50
52-wk low
$15.91
EPS
-$0.39
Beta
1.10
Shares outstanding
722.32M
No. of employees
721
Open
$35.22
High
$35.48
Low
$34.63
Mkt. cap
25.10B
Avg. vol.
9.02M
Volume
5.74M
52-wk high
$42.50
52-wk low
$15.91
EPS
-$0.39
Beta
1.10
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Simply Wall Street
·
20 hours ago
How $950 Million Settlement Will Impact Roivant Sciences Stock (ROIV)
Investing.com Canada
·
1 day ago
Form 4 Roivant Sciences Ltd. For: 6 October By Investing.com
Benzinga
·
2 days ago
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd